Upgrade to SI Premium - Free Trial

Intellia Therapeutics (NTLA)

14.25 -0.50 (3.39%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/30/26)

Latest Headlines

Intellia to present Phase 3 HAELO data at EAACI 2026 congress June 1, 2026 7:30 AM - StreetInsider Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026 June 1, 2026 7:30 AM - Globe NewsWire Intellia Therapeutics (NTLA) PT Lowered to $25 at H.C. Wainwright May 13, 2026 7:48 AM - StreetInsider Intellia Therapeutics (NTLA) PT Raised to $17 at Bernstein SocGen Group May 13, 2026 7:15 AM - StreetInsider Intellia short interest rises most among biotech stocks in latest period - Baird May 12, 2026 9:58 AM - StreetInsider Intellia Therapeutics (NTLA) PT Lowered to $49 at Canaccord May 12, 2026 6:36 AM - StreetInsider Intellia Therapeutics (NTLA) PT Raised to $50 at Jefferies May 11, 2026 4:24 PM - StreetInsider Intellia Therapeutics (NTLA) Tops Q1 EPS by 10c May 11, 2026 7:54 AM - StreetInsider Form 10-Q Intellia Therapeutics, For: Mar 31 May 11, 2026 7:50 AM - SEC Filing Form 8-K Intellia Therapeutics, For: May 11 May 11, 2026 7:36 AM - SEC Filing Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates May 11, 2026 7:30 AM - Globe NewsWire Intellia Therapeutics to Participate in Upcoming Investor Conferences May 5, 2026 7:30 AM - Globe NewsWire Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 1, 2026 4:01 PM - Globe NewsWire Form 8-K Intellia Therapeutics, For: Apr 27 April 30, 2026 4:32 PM - SEC Filing Form ARS Intellia Therapeutics, For: Dec 31 April 30, 2026 4:29 PM - SEC Filing Form DEFA14A Intellia Therapeutics, April 30, 2026 4:24 PM - SEC Filing Form DEF 14A Intellia Therapeutics, For: Jun 09 April 30, 2026 4:15 PM - SEC Filing Form SCHEDULE 13G Intellia Therapeutics, Filed by: VANGUARD CAPITAL MANAGEMENT LLC April 30, 2026 10:24 AM - SEC Filing Form 424B5 Intellia Therapeutics, April 29, 2026 5:29 PM - SEC Filing Intellia Therapeutics (NTLA) PT Lowered to $32 at Leerink Partners April 29, 2026 4:12 PM - StreetInsider Form SCHEDULE 13G Intellia Therapeutics, Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC April 29, 2026 1:49 PM - SEC Filing Intellia Therapeutics prices $180 million stock offering at $10.75 per share April 29, 2026 7:00 AM - StreetInsider Intellia Therapeutics Announces Pricing of Public Offering of Common Stock April 29, 2026 7:00 AM - Globe NewsWire Intellia Therapeutics (NTLA) PT Raised to $58 at Canaccord April 28, 2026 6:50 AM - StreetInsider Intellia Therapeutics (NTLA) PT Raised to $9 at Goldman Sachs April 28, 2026 6:10 AM - StreetInsider Intellia Therapeutics (NTLA) PT Raised to $30 at Citizens on Data that is 'Major Milestone' April 28, 2026 4:11 AM - StreetInsider Form 424B5 Intellia Therapeutics, April 27, 2026 5:19 PM - SEC Filing Intellia announces $150 million public stock offering April 27, 2026 4:01 PM - StreetInsider Intellia Announces Proposed Public Offering of Common Stock April 27, 2026 4:01 PM - Globe NewsWire Intellia Therapeutics (NTLA) PT Raised to $30 at Chardan April 27, 2026 2:50 PM - StreetInsider Intellia Therapeutics (NTLA) PT Raised to $35 at Leerink Partners April 27, 2026 1:10 PM - StreetInsider Intellia Therapeutics (NTLA) PT Raised to $15 at Morgan Stanley April 27, 2026 11:34 AM - StreetInsider TD Cowen on Intellia Therapeutics (NTLA): 'We see the Ph. III results as solid' April 27, 2026 10:48 AM - StreetInsider Intellia Therapeutics (NTLA) PT Raised to $13 at Baird April 27, 2026 10:15 AM - StreetInsider Intellia Therapeutics (NTLA) PT Raised to $20 at BofA Securities April 27, 2026 10:10 AM - StreetInsider Form 8-K Intellia Therapeutics, For: Apr 27 April 27, 2026 9:14 AM - SEC Filing Intellia begins rolling FDA submission for gene editing therapy April 27, 2026 7:03 AM - StreetInsider Intellia reports positive phase 3 results for gene editing HAE treatment April 27, 2026 7:00 AM - StreetInsider Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing April 27, 2026 7:00 AM - Globe NewsWire Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema April 27, 2026 7:00 AM - Globe NewsWire Intellia to report Phase 3 CRISPR gene editing trial data April 27 April 24, 2026 4:05 PM - StreetInsider Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026 April 24, 2026 4:05 PM - Globe NewsWire Form 8-K Intellia Therapeutics, For: Apr 07 April 10, 2026 4:17 PM - SEC Filing The Credibility Filter Wall Street Uses to Sort Biotech Winners April 8, 2026 9:15 AM - StreetInsider Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 3, 2026 4:05 PM - Globe NewsWire Form SCHEDULE 13G/A Intellia Therapeutics, Filed by: VANGUARD GROUP INC March 27, 2026 9:51 AM - SEC Filing Full Article List